<DOC>
	<DOC>NCT00445796</DOC>
	<brief_summary>Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on Day 14, of administration of Arsucam® as a single daily intake versus two daily intakes. Secondary Objective: To compare the clinical safety of the two treatment regimens.</brief_summary>
	<brief_title>Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>weighing ≥ 10 kg residing in the area covered by the investigating centre throughout the entire followup period axillary temperature ≥ 37.5 degrees Celsius or history of fever within the previous 24 hours Plasmodium falciparum density in the blood ranging from 1000 to 100,000 asexual forms per cubic millimetre presence of at least one sign of severe malaria or clinical danger sign : prostration, consciousness disorders, recent and repeated convulsions , respiratory distress, inability to drink, uncontrollable vomiting, macroscopic haemoglobinuria, jaundice, haemorrhagic shock, systolic Blood Pressure &lt; 70 mmHg in adults or &lt; 50 in children, spontaneous bleeding, inability to sit or stand serious concomitant disease allergy to one of the investigational medicinal products pregnant women or breastfeeding women. documented intake of an antimalarial at a suitable dosage within seven days prior to inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>